Literature DB >> 12039650

Early and persistent activation of myocardial apoptosis, bax and caspases: insights into mechanisms of progression of heart failure.

Gordon W. Moe1, George Naik, Andrea Konig, Xiangru Lu, Qingping Feng.   

Abstract

The aim of this study was to test the hypothesis that persistent myocardial apoptosis contributes to progression of heart failure in a canine model of pacing-induced cardiomyopathy. Dogs were paced at 250 beats per minute for 1 week (n=9), 3 weeks (n=14) and 4 weeks (n=14) with normal dogs served as controls (n=12). Myocardial apoptosis was assessed by multiple methods including DNA fragmentation and in situ terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining, bax and bcl-2 protein expression, and caspase activity. Pacing produced a progressive increase in left ventricular (LV) end diastolic pressure (LVEDP) and plasma norepinephrine levels with no significant increase in LV mass. The number of apoptotic cells was markedly increased after 1 week of pacing and remained increased at 4 weeks of pacing with characteristic DNA laddering. The increase in apoptosis was associated with bax protein expression and caspase activation while there was no detectable changes in bcl-2 protein expression. The estimated total number of apoptotic cells correlated with cardiac output and LVEDP (r=-0.69 and 0.59, respectively, P<0.001). Plasma norepinephrine and bax protein expression correlated significantly with the estimated total number of apoptotic myocytes (r=0.62 and 0.42, respectively, P<0.01). In conclusion, an early and persistent activation of myocardial apoptosis and pro-apoptotic factors is likely an important mechanism that contributes to the progression of heart failure in canine pacing-induced cardiomyopathy.

Entities:  

Year:  2002        PMID: 12039650     DOI: 10.1016/s0928-4680(02)00008-1

Source DB:  PubMed          Journal:  Pathophysiology        ISSN: 0928-4680


  8 in total

1.  Cell death in the pathogenesis and progression of heart failure.

Authors:  José Marín-García
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

2.  Akt signaling pathway in pacing-induced heart failure.

Authors:  Radha Ananthakrishnan; Gordon W Moe; Michael J Goldenthal; José Marín-García
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

Review 3.  Role of cell death in the progression of heart failure.

Authors:  Gordon W Moe; José Marín-García
Journal:  Heart Fail Rev       Date:  2016-03       Impact factor: 4.214

Review 4.  Alterations in mitochondrial function as a harbinger of cardiomyopathy: lessons from the dystrophic heart.

Authors:  Yan Burelle; Maya Khairallah; Alexis Ascah; Bruce G Allen; Christian F Deschepper; Basil J Petrof; Christine Des Rosiers
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

5.  Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures.

Authors:  Ilan Goldenberg; Asher Shainberg; Kenneth A Jacobson; Vladimir Shneyvays; Ehud Grossman
Journal:  Mol Cell Biochem       Date:  2003-10       Impact factor: 3.396

6.  The immunohistochemical evaluation of selected markers in the left atrium of dogs with end-stage dilated cardiomyopathy and myxomatous mitral valve disease - a preliminary study.

Authors:  Izabela Janus; Małgorzata Kandefer-Gola; Rafał Ciaputa; Agnieszka Noszczyk-Nowak; Urszula Pasławska; Massimiliano Tursi; Marcin Nowak
Journal:  Ir Vet J       Date:  2016-12-01       Impact factor: 2.146

7.  Sulforaphane, a Natural Isothiocyanate Compound, Improves Cardiac Function and Remodeling by Inhibiting Oxidative Stress and Inflammation in a Rabbit Model of Chronic Heart Failure.

Authors:  Tongliang Ma; Decai Zhu; Duoxue Chen; Qiaoyun Zhang; Huifang Dong; Wenwu Wu; Huihe Lu; Guangfu Wu
Journal:  Med Sci Monit       Date:  2018-03-12

8.  Chrysophanol Protects Against Acute Heart Failure by Inhibiting JNK1/2 Pathway in Rats.

Authors:  Xiao-Jiang Xie; Chang-Qing Li
Journal:  Med Sci Monit       Date:  2020-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.